 BOSTON and LOUISVILLE, Ky., June 01, 2022 GLOBE NEWSWIRE -- Talaris Therapeutics, Inc. Nasdaq: TALS, a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced it will host a conference call to discuss its presentations at the American Transplant Congress ATC and provide a data update from its ongoing Phase 3 FREEDOM-1 study in living donor kidney transplant LDKT recipients. 